Biomea Fusion, Inc. Common Stock (BMEA) is a publicly traded Healthcare sector company. As of May 21, 2026, BMEA trades at $1.33 with a market cap of $90.37M and a P/E ratio of -1.09. BMEA moved +9.84% today. Year to date, BMEA is +3.91%; over the trailing twelve months it is -15.29%. Its 52-week range spans $0.87 to $13.07. Analyst consensus is buy with an average price target of $7.20. Rallies surfaces BMEA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biomea Fusion Posts $12.4M Q1 Loss on $45.1M Cash Runway, Advances Clinical Trials: Biomea Fusion closed Q1 2026 with $45.1 million in cash, a net loss of $12.4 million compared with $29.3 million a year earlier, and projects cash runway into Q1 2027. It reported 52-week Phase II T1D data for icovamenib, initiated two Phase II T2D trials with topline data due Q4 2026; forecasts Phase I obesity data in Q2 2026.
| Metric | Value |
|---|---|
| Price | $1.33 |
| Market Cap | $90.37M |
| P/E Ratio | -1.09 |
| EPS | $-1.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.07 |
| 52-Week Low | $0.87 |
| Volume | 250 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.86M |
| Net Income | $-61.80M |
| Gross Margin | 0.00% |
6 analysts cover BMEA: 0 strong buy, 5 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.20.